Invivyd Reports Q3 Earnings Beat with $15.4 Million in Revenue
Invivyd, Inc. (IVVD) reported third-quarter financial results that exceeded analyst expectations for both earnings and revenue. The company posted a GAAP EPS of -$0.10, beating estimates by $0.03, while revenue reached $15.4 million, representing a 17.3% increase year-over-year and surpassing consensus by $0.36 million. As of September 30, the company maintained a strong liquidity position with $126.4 million in cash and cash equivalents. Despite the earnings beat, market attention remains focused on the company's clinical pipeline, specifically regarding LIBERTY Phase III topline data and the regulatory submission strategy for its VYD2311 therapy.

Tickers: $IVVD
Topics: cash position clinical trial data earnings beat revenue growth
Read the full article at Seeking Alpha
Part of the story Invivyd Reports Q3 Earnings Beat with $15.4 Million in Revenue (3 articles)